Adverse events290

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

21 to 40 of 290

Type	Event	Organ system	Group	Affected	At risk
other	Bradycardia	Cardiac disorders	Part A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 Injections	1	30
other	Bradycardia	Cardiac disorders	Part A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 Injections	1	30
other	Bradycardia	Cardiac disorders	Part A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 Injections	2	30
other	Bradycardia	Cardiac disorders	Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections	21	1,162
other	Bradycardia	Cardiac disorders	Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections	24	1,161
other	Nausea	Gastrointestinal disorders	Part A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 Injections	4	30
other	Nausea	Gastrointestinal disorders	Part A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 Injections	4	30
other	Nausea	Gastrointestinal disorders	Part A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 Injections	4	30
other	Nausea	Gastrointestinal disorders	Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections	182	1,162
other	Nausea	Gastrointestinal disorders	Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections	157	1,161
other	Administration site erythema	General disorders	Part A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 Injections	6	30
other	Administration site erythema	General disorders	Part A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 Injections	4	30
other	Administration site erythema	General disorders	Part A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 Injections	7	30
other	Administration site erythema	General disorders	Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections	116	1,162
other	Administration site erythema	General disorders	Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections	63	1,161
other	Administration site pain	General disorders	Part A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 Injections	25	30
other	Administration site pain	General disorders	Part A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 Injections	28	30
other	Administration site pain	General disorders	Part A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 Injections	28	30
other	Administration site pain	General disorders	Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections	862	1,162
other	Administration site pain	General disorders	Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections	582	1,161

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Previous page Next page

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03110770/events?page=2

API reference For AI assistants